Chipotle stock rebounds from early drop as CMG traders rethink 2026 outlook

Chipotle stock rebounds from early drop as CMG traders rethink 2026 outlook

New York, Feb 4, 2026, 15:35 EST — Regular session

  • Chipotle Mexican Grill shares rebounded to $40.00, up roughly 2.1%, in late U.S. trading following a steep drop earlier in the session.
  • The company’s cautious outlook for 2026 comparable sales and hints at modest menu price increases to counter rising costs triggered the moves. (Reuters)
  • Investors are keeping an eye on traffic trends, rising beef prices, and any new details in Chipotle’s upcoming SEC filing. (Chipotle InvestorRoom)

Shares of Chipotle Mexican Grill surged in the afternoon on Wednesday, bouncing back from a low of $36.50 to close near $40.00, up roughly 2.1%.

The bounce back followed Chipotle’s cautious 2026 outlook, which included a forecast for flat comparable restaurant sales—a key growth metric for existing stores. (Reuters)

Chipotle’s performance is crucial now, seen as a gauge of how much consumers will tolerate price hikes. If foot traffic continues to drop, expect the sector to pivot toward discounts and stricter cost management. (Reuters)

Chipotle reported fourth-quarter revenue of $3.0 billion, up 4.9%, despite a 2.5% drop in comparable sales and a 3.2% decline in transactions. The company added 132 new company-owned locations during the quarter and projects opening between 350 and 370 restaurants in 2026. It expects full-year comparable sales to remain “about flat.” (Chipotle InvestorRoom)

“2025 was a year of progress and resilience for Chipotle,” CEO Scott Boatwright said. He also outlined plans to advance a “Recipe for Growth” strategy focused on boosting transactions while enhancing speed and accuracy. (Chipotle InvestorRoom)

Management is focusing on modest price hikes. Chipotle expects to raise menu prices by roughly 1% to 2% this year but cautions that margins will remain squeezed amid rising expenses, particularly for beef, its largest commodity cost. (Reuters)

“The top-line guide was a disappointment,” Piper Sandler analysts said, highlighting ongoing weakness in demand across the wider restaurant sector. (Reuters)

Morningstar analyst Ari Felhandler pointed to risks, noting that increased marketing and menu efforts combined with modest price hikes “do not appear sufficient to propel positive comparable sales.” (Reuters)

Chipotle’s burrito bowls typically cost about $10.45. The chain has steered clear of deep discounts, even as competitors push value deals that could lure price-sensitive customers elsewhere. (Reuters)

Traders are weighing if store expansion can make up for weaker transaction numbers, and how quickly rising beef and labor costs will pressure restaurant margins. Chipotle promised more details in its annual report on Form 10-K, due early February. (Chipotle InvestorRoom)

The downside is clear: if lower-income customers continue to tighten their belts and beef prices stay high, even modest price hikes could further dent foot traffic and squeeze margins. (Reuters)

Investors are turning their focus to the upcoming 10-K filing for more details. Attention will also be on U.S. macroeconomic data related to consumer spending, such as the postponed January jobs report, now set for Feb. 11, and the January CPI report scheduled for Feb. 13. (Reuters)

Stock Market Today

  • Actinogen Medical and Top ASX Penny Stocks Show Potential Amid Market Headwinds
    February 4, 2026, 3:40 PM EST. The Australian stock market faces pressure from a Reserve Bank rate hike and international tech sell-offs, with ASX 200 futures hinting at a downturn. Yet, ASX penny stocks continue to offer investment opportunities due to their low price points and growth potential. Actinogen Medical (ASX:ACW), a pre-revenue biotechnology firm valued at A$153.2 million, is advancing its Alzheimer's treatment trial and recently secured A$17 million in funding. Despite current unprofitability, Actinogen's innovative approach could spur future revenue growth. Brisbane Broncos Limited (A$181.38 million market cap) operates debt-free in sports management, underlining stability. These stocks exemplify how smaller firms with strong fundamentals may thrive even amid broader market uncertainty.
Eli Lilly stock jumps as 2026 forecast beats estimates on Zepbound, Mounjaro demand
Previous Story

Eli Lilly stock jumps as 2026 forecast beats estimates on Zepbound, Mounjaro demand

Analog Devices stock jumps again — CEO sale filing, chip M&A and Feb. 18 earnings in focus
Next Story

Analog Devices stock jumps again — CEO sale filing, chip M&A and Feb. 18 earnings in focus

Go toTop